SR-BI and Antiviral Treatment Response in HCV

Influence of Scavenger Receptor Class B Type I (SR-BI) Gene Polymorphisms on Antiviral Treatment Response, and Metabolism in Chronic Hepatitis C Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02714712

Enrollment

309

Registered

2016-03-21

Start date

2015-08-31

Completion date

2016-08-31

Last updated

2017-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C

Brief summary

The scavenger receptor type B class I (SR-BI) is a receptor for high-density lipoproteins (HDL) and one of entry factors for hepatitis C virus (HCV). The investigators aimed to examine the association of single nucleotide polymorphisms (SNPs) of the SCARB1 gene, which encodes SR-BI, with virologic responses to pegylated interferon-based treatment in Asian chronic hepatitis C (CHC) patients.

Detailed description

1. Purpose of study: To examine the impacts of single nucleotide polymorphisms (SNPs) relevant to SR-BI on CHC patients. 2. Study Design To enroll 400 CHC patients during a 3-year period 3. Specify objectives of study when collecting extra specimen from participants Collect blood samples for genomic DNA to examine the SR-BI gene polymorphisms. 4. Expected Endpoints of Treatment Sustained virologic response (SVR) means undetectable serum HCV RNA levels 24 weeks after completion of antiviral therapy.

Interventions

DRUGPeginterferon alfa-2a

Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Naive to IFN treatment and other experimental antiviral or immunosuppressive therapy before enrollment. 2. Serum alanine aminotransferase levels, at least, twice the upper limit of normal on two occasions within the previous 6 months.

Exclusion criteria

1. Positive for hepatitis B surface antigen 2. Positive for human immunodeficiency virus antibody 3. Had a known history or evidence of autoimmune liver disease, inheritable disorders, renal insufficiency, malignancy 4. Had a history of daily alcohol consumption greater than 20 gram or active drug abuse.

Design outcomes

Primary

Measure	Time frame	Description
Serum HCV RNA levels	at 24 weeks after the end of treatment	sustained virologic response

Secondary

Measure	Time frame
serum fasting blood glucose levels	at 24 weeks after the end of treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026